1. Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol 1948;153:586-600.

1a. Alblas J, van Corven EJ, Hordjik PL, Milligan G, Moolenaar WH. Gi-mediated activation of the p21 ras-mitogen-activated protein kinase pathway by a2-adrenergic receptors expressed in fibroblasts. J Biol Chem 1993;268:22235-22238.

2. Anderson NG, Milligan G. Regulation of p42 and p44 MAP kinase isoforms in rat-1 fibroblasts stably transfected with a2-C10 adrenoceptors. Biochem Biophys Res Comm 1994;200:1529-1535.

3. Aoki C, Joh TH, Pickel VM. Ultrastructural localization of b-adrenergic receptor-like immunoreactivity in the cortex and neostriatum of rat brain. Brain Res 1987;437:264-282.

4. Barnes PJ. b-adrenergic receptors and their regulation. Am J Resp Crit Care Med 1995;152:838-860.

5. Benovic JL, Regan JW, Matsui H, et al. Agonist-dependent phosphorylation of the a2-adrenergic receptor by the b-adrenergic receptor kinase. J Biol Chem 1987;262:17251-17253.

6. Berlan M, Galitzky J, Montastruc JL. b3-adrenoceptor in the cardiovascular system. Fund Clin Pharmacol 1995;9:234-239.

7. Brodde OE. b-adrenoceptors in cardiac disease. Pharmacol Ther 1993;60:405-430.

8. Buccafusco JJ. Neuropharmacologic and behavioral actions of clonidine: Interactions with central neurotransmitters. Int Rev Neurobiol 1992;33:55-107.

9. Bylund DB, Blaxall HS, Iversen LJ, Caron MG, Lefkowitz RJ, Lomasney JW. Pharmacological characteristics of a2-adrenergic receptors: Comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol Pharmacol 1992;42:1-5.

10. Bylund DB. Subtypes of a1- and a2-adrenergic receptors. FASEB J 1992;6:832-839.

11. Bylund DB, Eikenberg DC, Hieble JP, et al. International union of pharmacology nomenclature of adrenoceptors. Pharmacol Rev 1994;46:121-136.

11a. Bylund DB, Ray-Prenger C, Murphy TJ. a2A and aa2B adrenergic receptor subtypes: antagonist binding in tissues and cell lines containing only one subtype. J Pharmacol Exp Ther 1988;245:600-601.

12. Chaudhry A, Mackenzie RG, Georgic LM, Granneman JG. Differential interaction of b1 and b3 adrenergic receptors with G1 in rat adipocytes. Cell Signal 1994;6:457-465.

13. Chruscinski AJ, Link RE, Daunt DA, Barsh GS, Kobilka BK. Cloning and expression of the mouse homolog of the human a2-C2 adrenergic receptor. Biochem Biophys Res Comm 1992;186:1280-1287.

14. Cocks TM, Angus JA. Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature 1983;305:627-630.

15. Convents A, De Backer J, Andre C, Vauquelin G. Desensitization of a2-adrenergic receptors in NG 108-15 cells by (-) adrenaline and phorbol 12-myristate 13-acetate. Biochem J 1989;262:245-251.

16. Corr PB, Shayman JA, Kramer JB, Kipnis RJ. Increased a-adrenergic receptors in ischemic cat myocardium. A potential mediator of electrophysiological derangements. J Clin Invest 1981;67:1232-1236.

17. Cotecchia S, Lattion AL, Diviani D, Cavalli A. Signaling and regulation of the a1B-adrenergic receptor. Biochem Soc Trans 1994;23:121-5.

18. Dalman HM, Neubig RR. Two peptides from the a2A-adrenergic receptor alter receptor G-protein coupling by distinct mechanisms. J Biol Chem 1991;266:11025-11029.

18a. De Boer T. The pharmacologic profile of mirtazepine. J Clin Psychiatry 1996;57:19-25.

19. Diverse-Pierluissi M, Inglese J, Stoffel RH, Lefkowitz RJ, Dunlap K. G-protein coupled receptor kinase mediates desensitization of norepinephrine-induced Ca2+ channel inhibition. Neuron 1996;16:579-585.

20. Dolen WK. The b2-adrenergic receptor and its agonists. Allergy Proc 1994;15:283-90.

21. Eason MG, Liggett SB. Subtype-selective desensitization of a2-adrenergic receptors. J Biol Chem 1992;267:25473-25479.

22. Eason MG, Liggett SB. Human a2-adrenergic receptor subtype distribution: Widespread and subtype selective expression of a2-C10, a2-C4, and a2-C2 mRNA in multiple tissues. Mol Pharmacol 1993;44:70-75.

23. Eason MG, Liggett SB. Chimeric mutagenesis of putative G-protein coupling domains of the a2A-Adrenergic receptor. J Biol Chem 1996;271:12826-12832.

24. Eason MG, Kurose H, Holt BD, Raymond JR, Liggett SB. Simultaneous coupling of a2-adrenergic receptors to two G-proteins with opposing effects. J Biol Chem 1992;267:15795-15801.

25. Eason MG, Moreira SP, Liggett SB. Four consecutive serines in the third intracellular loop are the sites for b-adrenergic receptor kinase-mediated phosphorylation and desensitization of the a2A-adrenergic receptor. J Biol Chem 1995;270:4681-4688.

26. Emorine LJ, Blin N, Strosberg AD. The human b3-adrenoceptor: the search for a physiological function. Trends Pharmacol Sci 1994;15:3-7.

27. Emorine LJ, Feve B, Pairault J, et al. The human b3-adrenergic receptor: relationship with atypical receptors. Am J Clin Nutrit 1992;55(1 Suppl.):215S-218S.

28. Erdbrügger W, Raulf M, Otto T, Michel MC. Does [3H]2-methoxy-idazoxan (RX 821002) detect more alpha-2-adrenoceptor agonist high-affinity sites than [3H] rauwolscine? A comparison of nine tissues and cell lines. J Pharmacol Exp Ther 1995;273:1287-1294.

29. Fox AW, Juberg EN, May JM, Johnson RD, Abel PW, Minneman KP. Thyroid status and adrenergic receptor subtypes in the rat: comparison of receptor density and responsiveness. J Pharmacol Exp Ther 1985;235:715-723.

30. Garcia-Sainz JA. a1-adrenergic action: receptor subtypes, signal transduction and regulation. Cell Signal 1993;5:539-547.

31. Gesek FA. a2-Adrenergic receptors activate phospholipase C in renal epithelial cells. Mol Pharmacol 1996;50:407-414.

32. Giacobino JP. b3-Adrenoceptor: an update. Eur J Endocrinol 1995;132:377-385.

33. Gleason MM, Hieble JP. The a2-adrenoceptors of the human retinoblastoma cell line (Y79) may represent an additional example of the a2c-adrenoceptor. Br J Pharmacol 1992;107:222-225.

34. Graham RM, Perez DM, Hwa J, Piascik MT. a1-adrenergic receptor subtypes. Circ Res 1996;78:737-749.

35. Haffner CA, Kendall MJ. Metabolic Effects of b2-agonists. J Clin Pharmacol Ther 1992;17:155-164.

36. Hamilton CA, Howe CA, Reid JL. Changes in brain a-adrenoceptors with increasing age in rabbits. Brain Res 1984;322:177-179.

37. Hayashi Y, Maze M. Alpha2 adrenoceptor agonists and anaesthesia. Br J Anaesth 1993;71:108-118.

38. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs and adrenergic receptor antagonists (Chapter 10). In: Goodman and Gilman's Pharmacological basis of therapeutics. 9th Edition, 1996.

38a. Jansson CC, Karp M, Oker-Blo C, Nasman J, Savola J, Akerman KEO. Two human a2 adrenoceptor subtypes a2A-C10 and a2B-C2 expressed in Sfg cells couple to transduction pathway resulting in opposite effects on cAMP production. Eur J Pharmacol 1995;290:75-83.

39. Jewell-Motz EA, Liggett SB. An acidic motif within the third intracellular loop of the a2-C2 adrenergic receptor is required for agonist-promoted phosphorylation and desensitization. Biochemistry 1995;34:11946-11953.

40. Jewell-Motz EA, Liggett SB. G protein coupled receptor kinase specificity for phosphorylation and desensitization of a2-adrenergic receptor subtypes. J Biol Chem 1996;271:18082-18087.

41. Jones SB, Halenda SP, Bylund DB. Alpha 2-adrenergic receptor stimulation of phospholipase A2 and of adenylate cyclase in transfected Chinese hamster ovary cells is mediated by different mechanisms. Mol Pharmacol 1991;39:239-245.

42. Keefer JR, Kennedy ME, Limbird LE. Unique structural features important for stabilization vs. polarization of the a2A-adrenergic receptor on the basolateral membrane of Madin-Darby canine kidney cells. J Biol Chem 1994;269:16425-16433.

43. Kennedy ME, Limbird LE. Mutations of the a2A-adrenergic receptor that eliminate detectable palmitoylation do not perturb receptor-G-protein coupling. J Biol Chem 1993;268:8003-8011.

44. Kobilka BK, Matsui H, Kobilka, et al. Cloning, sequencing, and expression of the gene coding for the human platelet a2-adrenergic receptor. Science 1987;238:650-656.

45. Kobilka BK, Kobilka TS, Daniel K, Regan JW, Caron MG, Lefkowitz RJ. Chimeric a2-, b2-adrenergic receptors: Delineation of domains involved in effector coupling and ligand binding specificity. Science 1988;240:1310-1316.

46. Krief S, Lonnqvist F, Raimbault S, et al. Tissue distribution of b3-adrenergic receptor mRNA in man. J Clin Invest 1993;91:344-349

47. Kurose H, Lefkowitz RJ. Differential desensitization and phosphorylation of three cloned and transfected a2-adrenergic receptor subtypes. J Biol Chem 1994;269:10093-10099.

48. Lakhlani PP, Lovinger DM, Limbird LE. Genetic evidence for involvement of multiple effector systems in a2A-adrenergic receptor inhibition of stimulus-secretion coupling. Mol Pharmacol 1996;50:96-103.

48a. Langer SZ. Presynaptic regulation of catecholamine release. Br J Pharmacol 1974;60:481-497.

49. Limbird LE. Receptors linked to inhibition of adenylate cyclase: Additional signaling mechanisms. FASEB J 1988;2:2686-2695.

50. Link R, Daunt D, Barsh G, Chruscinski A, Kobilka B. Cloning of two mouse genes encoding a2-adrenergic receptor subtypes and identification of a single amino acid in the mouse a2-C10 homolog responsible for an interspecies variation in antagonist binding. Mol Pharmacol 1992;42:16-27.

51. Link RE, Desai K, Hein L, et al. Cardiovascular regulation in mice lacking a2-adrenergic receptor subtypes b and c. Science 1996;273:803-805.

52. Liu J, Blin N, Conklin BR, Wess J. Molecular mechanisms involved in muscarinic acetylcholine receptor-mediated G-protein activation studied by insertion mutagenesis. J Biol Chem 1996;271:6172-6178.

53. Lomasney JW, Lorenz W, Allen LF, et al. Expansion of the a2-adrenergic receptor family: Cloning and characterization of a human a2-adrenergic receptor subtype, the gene for which is located on chromosome 2. Proc Nat Acad Sci USA 1990;87:5094-5098.

54. MacMillan LB, Hein L, Smith MS, Piascik MT, Limbird LE. Central hypotensive effects of the a2a-Adrenergic receptor subtype. Science 1996;273:801-803.

55. MacNulty EE, McClue SJ, Carr IC, Jess T, Wakelam MJ, Milligan G. a2-C10 adrenergic receptors expressed in rat-1 fibroblasts can regulate both adenylylcyclase and phospholipase D-mediated hydrolysis of phosphatidylcholine by interacting with pertussis toxin-sensitive guanine nucleotide-binding proteins. J Biol Chem 1992;267:2149-2156.

56. Manji HK, Schmidt ME, Grossman F, Dawkins K, Potter WZ. a2-Adrenergic receptors in the pathophysiology and treatment of depression. a2-Adrenergic receptors: Structure function and therapeutic implications. SM Lanier and LE Limberd Harwood Academic Publishers, Amsterdam, Netherland, eds. 1997.

56a. Marjamaki A, Luomala K, Ala-Uotila S, Scheinin M. Use of Recombinant human a2 adrenoceptors to characterize subtype selectivity of antagonist binding. Eur J Pharmacol 1993;246: 219-226.

57. Marullo S, Nantel F, Strosberg AD, Bouvier M. Variability in the regulation of b-adrenoceptor subtypes. Biochem Soc Trans 1993;23:127-129.

58. Maze M, Mizobe T. Clinical applications of a2 adrenergic agonists in the perioperative period- Neurobiologic considerations. a2-Adrenergic receptors: Structure, function and therapeutic implications. Lanier and Limbird, eds. 1997.

59. Minneman KP, Esbenshade TA. a1-adrenergic receptor subtypes. Ann Rev Pharmacol Toxicol 1994;34:117-133.

60. Mironneau J, Macrez-Lepretre N. Modulation of Ca2+ channels by a1A- and a2A-adrenoceptors in vascular myocytes: involvement of different transduction pathways. Cell Signal 1995;7:471-479.

61. Nicholas AP, Pieribone V, Hokfelt T Distributions of mRNAs for alpha-2 adrenergic receptor subtypes in rat brain: an in situ hybridization study. J Comp Neurol 1993;328:575-594.

62. O'Rourke MF, Iversen LJ, Lomasney JW, Bylund DB. Species orthologs of the alpha-2a adrenergic receptor: The pharmacological properties of the bovine and rat receptors differ from the human and porcine receptors. J Pharmacol Exp Ther 1994;1994;271:735-740.

63. Palacios JM, Kuhar MJ. b-adrenergic receptor localization by light microscopic autoradiography. Science 1980;208;1378-1380.

64. Pei G, Tiberi M, Caron MG, Lefkowitz RJ. An approach to the study of G-protein-coupled receptor kinases: An in vitro-purified membrane assay reveals differential receptor specificity and regulation by Gbg subunits. Proc Natl Acad Sci USA 1994;91:3633-3636.

65. Pitcher J, Lohse MJ, Codina J, Caron MG, Lefkowitz RJ. Desensitization of the isolated b-adrenergic receptors, b-adrenergic receptor kinase, cAMP-dependent protein kinase and protein kinase C occurs in distinct molecular mechanisms. Biochemistry 1992;31:3193-3197.

66. Rabin BC, Reid K, Guo TZ, Gustafsson E, Zhang C, Maze M. Sympatholytic and minimum anesthetic concentration-sparing responses are preserved in rats rendered tolerant to the hypnotic and analgesic action of dexmedetomidine, a selective a2-adrenergic agonist. Anesthesiology 1996;85:565-573.

67. Rainbow TC, Parsons B, Wolfe BB. Quantitative autoradiography of isolated b1- and b2-adrenergic receptors in the brain. Proc Natl Acad Sci USA 1984;81:1585-1589.

68. Regan JW, Kobilka TS, Yang-Feng TL, Caron MG, Lefkowitz RJ, Kobilka BK. Cloning and expression of a human kidney cDNA for an a2-adrenergic receptor subtype. Proc Nat Acad Sci USA 1988;85:6301-6305.

69. Rosin DL, Zeng D, Stornetta RL, et al. Immunohistochemical localization of a2a-Adrenergic receptors in catecholaminergic and other brainstem neurons in the rat. Neuroscience 1993;56:139-155.

70. Ruffolo RR, Hieble JP. a-Adrenoceptors. Pharmacol Ther 1994;61:1-64.

71. Ruffolo RR, Jr, Bondinell W, Hieble JP. a- and b-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem 1995;38:3681-3716.

72. Schwinn DA. Adrenergic receptors: unique localization in human tissues. Adv Pharmacol 1994;31:333-345.

72a. Starke K, Montel H, Gayk W, Merker R. Comparison of the effects of clonidine on pre- and postsynaptic adrenoceptors in the rabbit pulmonary artery. Naunyn Schmiedebergs Arch Pharmacol 1974;285:133-150.

73. Strader CD, Candelore MR, Hill WS, Sigal IS, Dixon RAF. Conserved aspartic acid residues 79 and 113 of the b-adrenergic receptor have different roles in receptor function. J Biol Chem 1988;263:10267-10271.

74. Strosberg AD. Structural and functional diversity of b-adrenergic receptors. Ann NY Acad Sci 1995;757:253-260.

75. Strosberg AD. Structure, function and regulation of the three b-adrenergic receptors. Obesity Res 1995;3(Suppl. 4):501S-505S.

76. Toews ML, Shreve PE, Bylund DB. Regulation of adrenergic receptors. In: Signaling mechanisms in secretory and immune cells. Martinez JR, Edwards BS, Seagrave JC, eds. by San Francisco Press, Inc. 1991;1-17.

77. Touhara K, Hawes BE, van Biesen T, Lefkowitz RJ. G-protein bg subunits stimulate phosphorylation of Shc adapter protein. Proc Nat Acad Sci USA 1995;92:9284-9287.

78. Unnerstall JR, Kopajtic TA, Kuhar MJ. Distribution of a2 agonist binding sites in the rat and human central nervous system: Analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents. Brain Res Rev 1984;7:69-101.

79. van Zwieten PA. Interaction between a- and b-adrenoceptor-mediated cardiovascular effects. J Cardiovasc Pharmacol 1986;5(Suppl.4):S21-S28.

80. van Zwieten PA, Maal JCA, de Jonge A, Wilffert B, Timmermans PBMWM. Central and Peripheral a-adrenoceptors. J Cardiovasc Pharmacol 1982;4:S19-S24.

81. Vargas HM, Gorman AJ. Vascular a1-adrenergic receptor subtypes in the regulation of arterial pressure. Life Sci 1995;57:2291-2308.

82. Wang R, MacMillan LB, Fremeau RT, Magnuson MA, Lindner J, Limbird LE. Expression of a2-adrenergic receptor subtypes in the mouse brain: Evaluation of spatial and temporal information imparted by 3 kb of 5' regulatory sequence for the a2A AR-receptor gene in transgenic animals. Neuroscience 1996;74:199-218.

83. Weinshank RL, Zgombick JM, Macchi M, et al. Cloning, expression, and pharmacological characterization of a human a2B -adrenergic receptor. Mol Pharmacol 1990;38:681-688.

84. Wilmot CA, Sullivan AC, Levin BE. Effects of diet and obesity on brain a1- and a2-noradrenergic receptors in the rat. Brain Res 1988;453:157-166.

85. Wilson AL, Guyer CA, Cragoe EJ, Limbird LE. The hydrophobic tryptic core of the porcine a2-adrenergic receptor retains allosteric modulation of binding by Na+, H+, and 5-amino-substituted amiloride analogs. J Biol Chem 1990;265:17318-17322.

86. Yamada S, Yamamura HI, Roeske WR. Characterization of a1-ARs in the heart using [3H]WB4101: effect of 6-hydroxydopamine treatment. J Pharmacol Exp Ther 1980;215:176-185.

Back to Chapter